Published in Circulation on March 01, 1986
Responses of plasma concentrations of A type natriuretic peptide and B type natriuretic peptide to alacepril, an angiotensin-converting enzyme inhibitor, in patients with congestive heart failure. Br Heart J (1994) 1.30
Flosequinan in heart failure: acute haemodynamic and longer term symptomatic effects. BMJ (1988) 1.01
The role of vasodilator therapy in the treatment of severe chronic heart failure. Drugs (1986) 1.01
Mortality in congestive heart failure: effects of vasodilator therapy. Br Med J (Clin Res Ed) (1987) 0.91
The control of adrenergic function in heart failure: therapeutic intervention. Heart Fail Rev (2000) 0.83
Muscle metaboreflex-induced coronary vasoconstriction limits ventricular contractility during dynamic exercise in heart failure. Am J Physiol Heart Circ Physiol (2013) 0.78
Therapeutic advances in heart failure. Cardiovasc Drugs Ther (1988) 0.75
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med (1996) 23.76
Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med (2011) 7.62
Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med (2001) 7.05
Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation (2000) 3.78
Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation (1999) 3.26
Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med (1997) 3.13
Renal and extrarenal hemodynamic effects of furosemide in congestive heart failure after acute myocardial infarction. N Engl J Med (1973) 2.79
Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation (1994) 2.74
Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators. N Engl J Med (1992) 2.72
ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). J Am Coll Cardiol (1999) 2.58
Mechanism of corepressor binding and release from nuclear hormone receptors. Genes Dev (1999) 2.57
Cloning, sequencing and expression of a Bacillus bacteriolytic enzyme in Escherichia coli. Mol Gen Genet (1988) 2.21
Coding and noncoding variation of the human calcium-channel beta4-subunit gene CACNB4 in patients with idiopathic generalized epilepsy and episodic ataxia. Am J Hum Genet (2000) 2.21
Paracrine regulation of angiogenesis and adipocyte differentiation during in vivo adipogenesis. Circ Res (2003) 2.12
Cytoplasmic dynein function is essential in Drosophila melanogaster. Genetics (1996) 2.10
Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther (2012) 2.09
Hemodynamic and metabolic responses to vasodilator therapy in acute myocardial infarction. Circulation (1973) 2.08
N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. Circulation (1994) 2.05
Immediate and sustained hemodynamic and clinical improvement in chronic heart failure by an oral angiotensin-converting enzyme inhibitor. Circulation (1980) 2.02
Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells. J Biol Chem (2003) 1.97
Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med (2001) 1.93
Electrocardiographic changes subsequent to artificial ventricular depolarization. Br Heart J (1969) 1.88
Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur Heart J (2000) 1.88
Vasodilator treatment for acute and chronic heart failure. Br Heart J (1977) 1.84
Heart-block following acute myocardial infarction. Treatment with demand and fixed-rate pacemakers. Lancet (1968) 1.77
Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. Eur Heart J (1999) 1.76
Comparison of transesophageal echocardiographic and scintigraphic estimates of left ventricular end-diastolic volume index and ejection fraction in patients following coronary artery bypass grafting. Anesthesiology (1990) 1.75
Ventricular contraction abnormalities in dilated cardiomyopathy: effect of biventricular pacing to correct interventricular dyssynchrony. J Am Coll Cardiol (2000) 1.73
A beta 4 isoform-specific interaction site in the carboxyl-terminal region of the voltage-dependent Ca2+ channel alpha 1A subunit. J Biol Chem (1998) 1.71
Metabolic and hemodynamic consequences of sodium bicarbonate administration in patients with heart disease. Am J Med (1989) 1.70
The role of vasodilator therapy in heart failure. Prog Cardiovasc Dis (1977) 1.69
Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. J Am Coll Cardiol (1998) 1.67
Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation (1994) 1.67
Tolerance to intravenous nitroglycerin in patients with congestive heart failure: role of increased intravascular volume, neurohumoral activation and lack of prevention with N-acetylcysteine. J Am Coll Cardiol (1990) 1.66
Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate. J Am Coll Cardiol (1994) 1.66
Heart failure therapy in evolution. Circulation (1996) 1.64
Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation (1998) 1.63
Long-term digitalis therapy improves left ventricular function in heart failure. N Engl J Med (1980) 1.63
The influence of left ventricular filling pressure on atrial contribution to cardiac output. Am Heart J (1979) 1.63
Polymorphous ventricular tachycardia associated with acute myocardial infarction. Circulation (1991) 1.61
Hybridization of filters with competitor DNA in the liquid phase in a standard and a micro-assay. Biochimie (1974) 1.60
Hemodynamic and metabolic effects of isosorbide dinitrate in chronic congestive heart failure. Am Heart J (1975) 1.58
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Detection and characterization of acute myocardial infarction in man with use of gated magnetic resonance. Circulation (1985) 1.55
Alterations in left ventricular function and coronary hemodynamics with captopril, hydralazine and prazosin in chronic ischemic heart failure: a comparative study. Circulation (1982) 1.54
Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus. N Engl J Med (1988) 1.54
Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study. Eur Heart J (1998) 1.52
Bronchial hyperresponsiveness to inhaled methacholine in subjects with chronic left heart failure at a time of exacerbation and after increasing diuretic therapy. Chest (1989) 1.52
A human homologue of the Drosophila melanogaster diaphanous gene is disrupted in a patient with premature ovarian failure: evidence for conserved function in oogenesis and implications for human sterility. Am J Hum Genet (1998) 1.50
The risk of pacing after infarction, and current recommendations. Lancet (1969) 1.50
Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med (1981) 1.49
A new impedance cardiograph device for the non-invasive evaluation of cardiac output at rest and during exercise: comparison with the "direct" Fick method. Eur J Appl Physiol (2000) 1.49
The 2002/3 Canadian Cardiovascular Society consensus guideline update for the diagnosis and management of heart failure. Can J Cardiol (2003) 1.49
Non-invasive cardiac output evaluation during a maximal progressive exercise test, using a new impedance cardiograph device. Eur J Appl Physiol (2001) 1.47
Reduced pulmonary clearance of endothelin-1 contributes to the increase of circulating levels in heart failure secondary to myocardial infarction. Circulation (1998) 1.45
Medical therapy of acute myocardial infarction by application of hemodynamic subsets (first of two parts). N Engl J Med (1976) 1.45
Markers for transfusion-transmissible infections in north Indian voluntary and replacement blood donors: prevalence and trends 1989-1996. Vox Sang (1997) 1.44
Testosterone relaxes rabbit coronary arteries and aorta. Circulation (1995) 1.42
Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am J Physiol (1990) 1.41
Interstudy reproducibility of dimensional and functional measurements between cine magnetic resonance studies in the morphologically abnormal left ventricle. Am Heart J (1990) 1.40
The noninvasive diagnosis of right ventricular infarction. Circulation (1978) 1.39
Recovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early afterload reducing therapy study. Ann Intern Med (2001) 1.39
Effects of vasodilator therapy for severe pump failure in acute myocardial infarction on short-term and late prognosis. Circulation (1976) 1.37
Chemical synthesis and characterization of maurocalcine, a scorpion toxin that activates Ca(2+) release channel/ryanodine receptors. FEBS Lett (2000) 1.36
Beneficial effects of vasodilator agents in severe mitral regurgitation due to dysfunction of subvalvar apparatus. Circulation (1973) 1.36
Long-term vasodilator therapy for heart failure: clinical response and its relationship to hemodynamic measurements. Circulation (1981) 1.35
Quality of sleep and its daily relationship to pain intensity in hospitalized adult burn patients. Pain (2001) 1.33
Optimal level of filling pressure in the left side of the heart in acute myocardial infarction. N Engl J Med (1973) 1.32
Oral hydralazine therapy for chronic refractory heart failure. Circulation (1976) 1.30
Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol (1999) 1.30
Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res (1994) 1.30
Testosterone induces dilation of canine coronary conductance and resistance arteries in vivo. Circulation (1996) 1.30
A new beta subtype-specific interaction in alpha1A subunit controls P/Q-type Ca2+ channel activation. J Biol Chem (1999) 1.30
Medical therapy of acute myocardial infarction by application of hemodynamic subsets (second of two parts). N Engl J Med (1976) 1.28
Myofibroblasts in the stroma of invasive and metastatic carcinoma: a possible host response to neoplasia. Am J Surg Pathol (1979) 1.27
Depression of left ventricular function due to acute myocardial ischemia and its reversal after aortocoronary saphenous-vein bypass. N Engl J Med (1972) 1.27
The cavity electrocardiogram in emergency artificial pacing. Postgrad Med J (1969) 1.27
Emergency bypass surgery in impending and complicated acute myocardial infarction. Arch Surg (1972) 1.27
Influence of direct myocardial revascularization on left ventricular asynergy and function in patients with coronary heart disease. With and without previous myocardial infarction. Circulation (1973) 1.26
Fall of endocardial potentials after acute myocardial infarction. Lancet (1970) 1.26
Effect of infarct artery patency on prognosis after acute myocardial infarction. The Survival and Ventricular Enlargement Investigators. Circulation (1995) 1.26
Epicardial and endocardial mapping of ventricular tachycardia in patients with myocardial infarction. Is the origin of the tachycardia always subendocardially localized? Circulation (1991) 1.25
Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann Intern Med (1982) 1.24
Transgenic mice carrying the mouse mammary tumor virus ras fusion gene: distinct effects in various tissues. Mol Cell Biol (1989) 1.24
Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol (1994) 1.24
Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation (2001) 1.23
Dysfunction of the beta- and alpha-adrenergic systems in a model of congestive heart failure. The pacing-overdrive dog. Circ Res (1991) 1.22
Bradykinin and des-Arg(9)-bradykinin metabolic pathways and kinetics of activation of human plasma. Am J Physiol Heart Circ Physiol (2001) 1.21
Vasodilator therapy for acute myocardial infarction and chronic congestive heart failure. J Am Coll Cardiol (1983) 1.18
Modulation of plasma and platelet vasopressin by cardiac function in patients with heart failure. Kidney Int (1986) 1.16